Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Current Assets (2020 - 2026)

Climb Bio filings provide 7 years of Current Assets readings, the most recent being $113.4 million for Q1 2026.

  • Quarterly Current Assets rose 13.09% to $113.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $113.4 million through Mar 2026, up 13.09% year-over-year, with the annual reading at $105.8 million for FY2025, 31.65% down from the prior year.
  • Current Assets hit $113.4 million in Q1 2026 for Climb Bio, up from $105.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $226.0 million in Q2 2024 and bottomed at $87.4 million in Q2 2025.
  • Average Current Assets over 5 years is $128.0 million, with a median of $114.2 million recorded in 2023.
  • The largest annual shift saw Current Assets skyrocketed 97.82% in 2024 before it tumbled 61.33% in 2025.
  • Climb Bio's Current Assets stood at $134.4 million in 2022, then fell by 17.96% to $110.3 million in 2023, then skyrocketed by 40.47% to $154.9 million in 2024, then crashed by 31.65% to $105.8 million in 2025, then increased by 7.14% to $113.4 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Current Assets are $113.4 million (Q1 2026), $105.8 million (Q4 2025), and $91.0 million (Q3 2025).